A practical reference on thymosin beta-4: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-12 and is reviewed periodically as new material appears.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3,108 Da | Consistent with a 28-residue acetylated peptide |
| Residue count | 28 | Corresponds to the amino terminal region of prothymosin alpha |
| Appearance of dry powder | White to off-white solid | Slight variation between lots is normal |
| Solubility class | Freely soluble in water | Low solubility in most organic solvents |
| Common synonyms | Thymosin alpha 1, T alpha 1 | The numeral reflects an early fraction numbering scheme |
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Vitamin A deficiency is common in developing countries but rarely seen in developed countries. Approximately 250,000 to 500,000 malnourished children in the developing world go blind each year from a deficiency of vitamin A. Vitamin A deficiency in expecting mothers increases the mortality rate of children shortly after childbirth. Night blindness is one of the first signs of vitamin A deficiency. Vitamin A deficiency contributes to blindness by depleting the necessary form needed for rhodopsin.
One of the most prominent campaigners was a young man from East Germany called Rudi Dutschke who also criticised the forms of capitalism that were to be seen in West Berlin. Just before Easter 1968, a young man tried to kill Dutschke as he bicycled to the student union, seriously injuring him. All over West Germany, thousands demonstrated against the Springer newspapers which were seen as the prime cause of the violence against students. Trucks carrying newspapers were set on fire and windows in office buildings broken. In the wake of these demonstrations, in which the question of America's role in Vietnam began to play a bigger role, came a desire among the students to find out more about the role of the parent-generation in the Nazi era. The proceedings of the War Crimes Tribunal at Nuremberg had been widely publicised in Germany; the attorney Fritz Bauer gathered evidence on the guards of the Auschwitz concentration camp, and about twenty were put on trial in Frankfurt in 1963. Daily newspaper reports and visits by school classes to the proceedings revealed to the German public the nature of the concentration camp system, and it became evident that the Shoah was of vastly greater dimensions than the German population had believed. The term "Holocaust" for the systematic mass-murder of Jews first came into use in 1979, when a 1978 American mini-series with that name was shown on West German television. The processes set in motion by the Auschwitz trial reverberated decades later.
==== MeSH D12.776.467.374.200 – chemokines ==== MeSH D12.776.467.374.200.070 – beta-thromboglobulin MeSH D12.776.467.374.200.100 – chemokines, c MeSH D12.776.467.374.200.110 – chemokines, cc MeSH D12.776.467.374.200.120 – chemokines, cxc MeSH D12.776.467.374.200.130 – chemokines, cx3c MeSH D12.776.467.374.200.508 – interleukin-8 MeSH D12.776.467.374.200.600 – macrophage inflammatory proteins MeSH D12.776.467.374.200.600.500 – macrophage inflammatory protein-1 MeSH D12.776.467.374.200.610 – monocyte chemoattractant proteins MeSH D12.776.467.374.200.610.600 – monocyte chemoattractant protein-1 MeSH D12.776.467.374.200.700 – platelet factor 4 MeSH D12.776.467.374.200.750 – rantes
Sources: en.wikipedia.org
== Use and effects == In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists 2,5-DMA's dose as 80 to 160 mg orally and its duration is 6 to 8 hours. Information on the qualitative effects of 2,5-DMA is said to be very sparse. According to Shulgin, it produced threshold effects or a "plus-one" on the Shulgin Rating Scale at a dose of 80 mg orally, with the effects being completely physical and including tremors, some cardiovascular effects, and no sensory effects. He opted not to try higher doses. Other reports were also reviewed in PiHKAL. According to a report from South America, a dose of 75 mg produced a largely pleasant intoxication, including increased interest in one's surroundings, but with no perceptual changes, no overt stimulation, and no physiological effects aside from slight pupil dilation. One other report of 250 mg 2,5-DMA tartrate, which would be equivalent to somewhere in the range of 150 to 200 mg of the hydrochloride salt, produced some "speedy" or amphetamine-like effects but no sensory changes. In an earlier review, Shulgin reported that 2,5-DMA produced stimulant-like effects at a dose of 50 mg, with effects including vertigo, a "closed visual field", slight muscular incoordination, modest central intoxication, slightly increased blood pressure, and "extreme hyperactivity". The onset was reported to be 1 hour and peak effects after 2 hours, with a total duration of 5 hours.
where Bn is the binding energy of the captured electron. Because the binding energy of the electron is much less than the mass of the electron, nuclei that can undergo β+ decay can always also undergo electron capture, but the reverse is not true.
Subsequent research suggests that multiple waves of immune cells develop through hematopoiesis from hemogenic endothelial cells (ECs), independent of HSCs, with HSCs arising in a later hematopoietic wave. Tissue-resident immune cells may be either fetal-derived or the progeny of adult HSCs. In vertebrates, the earliest source of mast cells is the extraembryonic yolk sac, where blood and immune cells first develop. However, there are differences in the embryonic development of vertebrates such as mice compared to primates (including humans). In primates, yolk sac formation involves a transient primary yolk sac, and the formation of extraembryonic mesoderm, prior to generation of a secondary yolk sac where the first blood cells of the embryo develop. During embryonic development, mast cell progenitors (MCps) form in a series of developmentally discrete waves. The first wave of mast cells in the embryo is derived from erythro-myeloid progenitors (EMPs) in the yolk sac, before hematopoietic stem cells (HSC) emerge. In mouse models, the earliest mast cell progenitors originate in the embryo around embryonic day 7 (E7.5-E8.5). Transient erythro-myeloid progenitors (EMPs) develop in the yolk sac between E8.5-E10.5 and in fetal liver (FL) between E11.5-E13.5. Embryonic multipotent progenitors (eMPPs) and hematopoietic stem cells (HSCs) emerge around E10.5. Mast cell differentiation in the fetal liver (FL) starts from E11, along with a peak in the number of mast cell progenitors.
Sources: en.wikipedia.org
The name reflects an early convention for naming thymus-derived fractions. The peptide is characterized and measured as a defined molecule, and it does not operate through a single classical endocrine axis.
It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.
Thymosin alpha-1 is a single defined 28-residue peptide, while the broader family includes unrelated peptides such as thymosin beta-4. The shared name reflects historical isolation from thymus tissue rather than a common structure. Confusion between the two is common in older literature.
No single pathway fully accounts for its reported effects. Several studies describe interaction with innate immune receptors and downstream cytokine changes, but the complete picture is not settled. Open questions remain about which effects occur at physiological concentrations.